
About Otricath
Otricath is a Healthcare company based in Houston (United States) founded in 2016. A closed-loop catheter system is developed for liver cancer treatment. Otricath offers products and services including Otricath Platform and Therapy Delivery Device. Its focus areas include Life Sciences, Oncology, Medical Devices and Therapies. Its legal entity is NHC, LLC. Its competitors include TriSalus Life Sciences, Cooler Heads and Cognos Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Otricath was founded in 2016 in Houston, United States, within the medical device sector focused on oncology. A closed-loop catheter system is being developed to deliver treatment agents directly to liver tumor sites and extract them post-treatment. This approach is intended to limit agent migration to other body areas, thereby reducing side effects compared to conventional delivery methods. Operations center on advancing this technology for safer cancer interventions.
- Headquarters Houston, United States
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website otricath.com
- Social X
- Legal Name Nhc, Llc
Products & Services of Otricath
Otricath offers a comprehensive portfolio of products and services, including Otricath Platform and Therapy Delivery Device.
Delivers cancer-fighting agents to solid tumors with control and safety.
Provides predictable and safe agent delivery for cancer treatment.
Competitors of Otricath
Otricath has 3 listed competitors in our database, 3 of them funded. They include TriSalus Life Sciences, Cooler Heads and Cognos Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| trisaluslifesci.com | 2009 | Westminster, United States | $83.37M | 100 | Developer of drug delivery devices to treat cancers | |
| coolerheads.com | 1998 | San Diego, United States | $23.11M | Developer of cold cap system to prevent chemotherapy side effects | ||
| cognosthx.com | 2015 | Los Angeles, United States | $5.75M | 13 | Cognos Therapeutics is focused on innovative neurological and oncological treatments. |
Detailed competitors of Otricath
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Otricath (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Otricath
Otricath was founded in 2016.
Otricath is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
Otricath was founded in 2016 in Houston, United States, within the medical device sector focused on oncology. A closed-loop catheter system is being developed to deliver treatment agents directly to liver tumor sites and extract them post-treatment. This approach is intended to limit agent migration to other body areas, thereby reducing side effects compared to conventional delivery methods. Operations center on advancing this technology for safer cancer interventions.
Otricath's top competitors include TriSalus Life Sciences, Cooler Heads and Cognos Therapeutics.
Otricath offers Otricath Platform and Therapy Delivery Device.
Otricath operates through Nhc, Llc.